The osteoporosis pill in your past and the socket that will not close

Let me concede the part that prevents unnecessary fear, because it is genuinely reassuring and it is correct. The osteoporosis drugs that most people take, the oral antiresorptives, carry a far lower risk of jaw necrosis after a tooth extraction than the high-dose intravenous versions used in cancer treatment. The difference is not subtle: the estimated incidence of osteonecrosis with oral bisphosphonates is a small fraction of that seen with intravenous use in oncology patients [1]. Most people who take an osteoporosis pill and need a tooth out will heal a socket normally. So this is not a piece arguing that anyone on an osteoporosis drug should never have an extraction, or that the drugs make dental surgery dangerous. For the great majority, they do not.

The pivot is that “low” is not “zero,” and the thing that tells you where in the low range a given patient sits is a question the tourism intake form almost never asks. Medication-related osteonecrosis of the jaw, MRONJ, is most often precipitated by a dental extraction; the majority of recorded cases follow one [1]. The variable that stratifies an individual’s risk before that extraction is not simply whether they take an antiresorptive, but how much of it has accumulated in their bone over how long [1] [2]. A short tick-box that records “osteoporosis medication: yes” has captured the least useful version of the answer. The socket that will not close, weeks later and a continent away, is where that skipped follow-up question finally makes itself heard.

The reassurance is real, and it points to the missing question

Antiresorptive drugs work by suppressing the cells that break down old bone, slowing the constant turnover by which bone renews itself. That is therapeutic in osteoporosis, where bone is being lost too fast. The unintended consequence in the jaw is that bone which has had its renewal suppressed can struggle to heal and remodel after the trauma of an extraction, and in a minority of patients the exposed bone fails to cover over, producing osteonecrosis [1] [2]. The oral osteoporosis doses are low enough that this is uncommon, which is exactly why the optimistic framing holds. But the same mechanism that makes the risk low at short exposure makes it rise with cumulative exposure.

Bisphosphonates are the clearest example, because they do not simply act and clear. They embed in bone and persist there, so the suppression of turnover, and therefore the risk, can remain elevated even after the drug is stopped, sometimes for years [1] [2]. This is the fact that turns “do you take an osteoporosis drug” into a poor question and “how long have you taken it, and when did you stop” into the useful one. A patient who took a bisphosphonate for many years and stopped two years ago is not risk-free simply because the prescription has ended. The drug is still in the bone. A patient who started six months ago sits in a different band again. None of this is exotic specialist knowledge. It is the standard basis on which the risk is stratified, and it depends entirely on a history being taken properly.

Denosumab and why the disclosure has to be wider than “bisphosphonate”

There is a second drug class the intake conversation has to cover, and patients frequently do not know it counts. Denosumab is a different kind of antiresorptive, given by injection, also used in osteoporosis at one dose and in cancer at another, and it is also associated with MRONJ [1] [3]. A patient who answers “no” to a question about bisphosphonates because they were given a denosumab injection at the clinic, and never connected the two, has truthfully answered the wrong question. The clinically relevant category is any antiresorptive history, not one specific pill.

There is one practical contrast worth knowing. Because bisphosphonates persist in bone and denosumab’s effect is tied more closely to its ongoing dosing schedule, the duration-and-timing question takes a slightly different shape for each [2] [3]. But the conclusion for a patient facing an extraction is identical: the dentist needs to know about any antiresorptive, by injection or by mouth, current or past, for osteoporosis or anything else. The breadth of the disclosure is the safeguard, and it is precisely the breadth that a short, translated, tick-box intake form tends to collapse into a single ambiguous line.

WHAT THE INTAKE FORM ASKS vs WHAT STRATIFIES THE RISK

  TYPICAL TOURISM INTAKE          WHAT ACTUALLY MATTERS FOR EXTRACTION
  ----------------------          ------------------------------------
  "Osteoporosis meds? Y / N"      Which drug exactly (bisphosphonate,
                                    denosumab, other antiresorptive)?

  (often no follow-up)            Oral or intravenous / injected?

  (drug stopped years ago         How many YEARS of cumulative use?
   may be answered "No")           Bisphosphonates persist in bone,
                                    so "stopped" is not "cleared."

  (denosumab injection may not    When was the last dose / when stopped?
   be recognised as relevant)

  Captured: a single yes/no       Needed: drug + route + DURATION +
                                    timing -> a risk BAND, not a flag

  The form records the least informative version of the answer.
  The non-healing socket reads out the version the form skipped.

The diagram is the whole argument in one frame. The information that would place a patient in a higher or lower MRONJ risk band exists, is standard, and is obtainable by asking three or four more questions. The tourism intake form, optimised for speed and signed under time pressure in a second language, tends to capture only the top line. The gap between what was asked and what mattered is not filled in the operating chair. It is filled, if at all, by the socket itself, weeks later.

Why the socket announces it after you have flown home

The timing is the cruelty. A normal extraction socket clots, then closes over with soft tissue within a couple of weeks [4]. MRONJ does not run on that schedule. The exposed, non-healing bone can take weeks to declare itself, and by definition it is the failure of healing that defines it, so it shows up after the window in which a normal socket would already have closed [1] [4]. In the one-trip tourism model, that delay maps almost exactly onto the flight home. The patient leaves with a socket that looks like every other early socket, and the distinguishing feature, bone that will not cover over, emerges once they are back in their own country, far from the clinic that did the extraction and that holds whatever scant history it took.

At home, this is recoverable because the chain is intact: the dentist who did the extraction took a proper drug history, knew the patient was on an antiresorptive, was watching for delayed healing, and is reachable when the socket does not close. Abroad, every link in that chain is weaker. The history may never have captured the duration. The dentist who operated cannot follow up. The patient’s home dentist, now managing an exposed-bone complication, is reverse-engineering a drug history and an operative record that should have been the first thing established and the easiest thing to obtain. The risk was always stratifiable in advance. It was the advance assessment that the model skipped.

The questions that change the answer

Because the risk is real but low and the stratifier is a history rather than a procedure, the questions that matter interrogate the history-taking, not the surgeon’s technique.

1. Did the clinic ask how long I have taken any antiresorptive drug, including ones I stopped years ago? This is the decisive one. Duration and persistence are what move a patient between risk bands, and bisphosphonates remain in bone after the prescription ends. A form that asked only whether you currently take an osteoporosis drug has not assessed your risk; it has noted a flag without reading it.

2. Does my disclosure include denosumab and any injected antiresorptive, not just pills I take by mouth? This tests the breadth of the conversation. Patients routinely fail to mention an injection they did not connect to the dental question. If neither you nor the form makes the category wide enough, a relevant exposure can be truthfully omitted.

3. Does the plan allow any delayed non-healing to be reviewed before I fly home? This connects the biology to the itinerary. MRONJ tends to declare itself after a normal socket would have closed, which in a one-trip schedule is after departure. A plan that books the flight inside the healing window guarantees that the complication this drug history predicts will surface where the operating clinic cannot see it.

The bottom line

The oral osteoporosis drugs carry a far lower jaw-necrosis risk after extraction than the intravenous cancer doses, and most patients on them heal normally. I have kept that concession central because it is true and because frightening osteoporosis patients away from necessary dental care would be its own harm. But low is not zero, and the variable that tells you where a given patient sits in the low range is duration of antiresorptive exposure, including drugs stopped years ago, because bisphosphonates persist in the bone long after the prescription ends. That stratifying question is standard, obtainable, and routinely absent from a brief tourism intake form, which records only whether you take an osteoporosis drug, not for how long, and often misses injected denosumab entirely. The non-healing socket is not where the mistake is made. It is where a skipped history, weeks later and a continent away, finally reads itself out as exposed bone that will not close. If the intake never asked how long you were on the drug, the risk assessment this extraction depends on simply was not done.

For the related antiresorptive question framed around a single decisive intake item, see the one intake question that flags MRONJ risk. On other drug-history gaps the tourism intake leaves open, see who manages your warfarin and bridging abroad and the drug-interaction void around overseas antibiotics. On records and follow-up after a complication surfaces at home, see the records to obtain before leaving a dental clinic abroad and the failing implant eight months later in an Australian dentist’s chair. On the broader pattern, see the dental tourism trust gap. Our standing methodology and disclosures explain how these pieces are built.